Peter Shao

Vice President, Head of Technical Operations at SciClone Pharmaceuticals Inc

Peter Shao has extensive work experience in the pharmaceutical industry. Peter began their career as an Analytical Chemist at Noven Pharmaceuticals in 1993. Peter then worked as a Supervisor in Analytical R&D at Actavis, Inc. from 1997 to 1998. Peter joined Oread Inc. in 1998 as a Scientist III/Supervisor. In 2000, they joined Novartis, where they served as a Manager in Quality Control until 2007. Peter then joined Jazz Pharmaceuticals as an Associate Director of Quality Sciences from 2007 to 2008. Peter worked as the Director of Quality at Sagent (China) Pharmaceutical Co., Ltd. from 2008 to 2009. Peter served as the General Manager for China at Flavine North America from 2009 to 2011. Peter then joined AbbVie Inc. as a Senior Manager in Quality Assurance from 2011 to 2012. Peter's most recent role was at SciClone Pharmaceuticals, where they held various positions including Senior Director of Quality, Vice President of Quality, and Vice President Head of Technical Operations.

Peter Shao holds a Bachelor's Degree in Marine Chemistry from Xiamen University. Peter further pursued their education at Florida International University, where they obtained a Master's Degree in Analytical Chemistry. Peter then enrolled at San Jose State University to pursue an MBA.

Location

San Mateo, United States

Links

Previous companies


Org chart


Teams


Offices


SciClone Pharmaceuticals Inc

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.


Industries

Employees

501-1,000

Links